Advertisement

Topics

Here's Why Allergan Stock Might Be an Incredible Bargain After Dropping 9.9% in August

16:07 EDT 11 Sep 2017 | Topix

The specialty drugmaker's shares were apparently brought down by its loose association with Teva Pharmaceutical Industries Ltd. via its 9.9% stake in the Israeli drugmaker, as well as its former ties to the struggling generic drug industry. As a reminder, Allergan sold its massive generic drug business to Teva last year in an equity and cash deal valued at $40.5 billion.

Original Article: Here's Why Allergan Stock Might Be an Incredible Bargain After Dropping 9.9% in August

NEXT ARTICLE

More From BioPortfolio on "Here's Why Allergan Stock Might Be an Incredible Bargain After Dropping 9.9% in August"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...